Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ELDN Eledon Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ELDN
Price (delayed)
$3.03
Market cap
$181.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.97
Enterprise value
$173.83M
Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring
Highlights
The quick ratio has increased by 35% year-on-year and by 12% since the previous quarter
The debt has declined by 8% since the previous quarter
Eledon Pharmaceuticals's EPS has surged by 80% YoY but it has decreased by 29% QoQ
The net income has soared by 70% YoY but it has contracted by 7% from the previous quarter
The company's equity fell by 3% QoQ
Key stats
What are the main financial stats of ELDN
Market
Valuations
Earnings
Shares outstanding
59.88M
Market cap
$181.44M
Enterprise value
$173.83M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.58
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$77.67M
Net income
-$38.71M
EBIT
-$38.28M
EBITDA
-$37.94M
Free cash flow
-$54.59M
Per share
Balance sheet
Liquidity
EPS
-$0.97
EPS diluted
-$0.97
Free cash flow per share
-$0.71
Book value per share
$1.91
Revenue per share
$0
TBVPS
$2.09
Total assets
$161.31M
Total liabilities
$46.73M
Debt
$880,000
Equity
$114.58M
Working capital
$118.53M
Debt to equity
0.01
Current ratio
13.91
Quick ratio
13.6
Net debt/EBITDA
0.2
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27%
Return on equity
-51.6%
Return on invested capital
-32.2%
Return on capital employed
-25.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELDN stock price
How has the Eledon Pharmaceuticals stock price performed over time
Intraday
-4.42%
1 week
-3.81%
1 month
-8.46%
1 year
5.57%
YTD
-26.46%
QTD
-10.62%
Financial performance
How have Eledon Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$77.67M
Net income
-$38.71M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 82% year-on-year and by 10% since the previous quarter
The net income has soared by 70% YoY but it has contracted by 7% from the previous quarter
Price vs fundamentals
How does ELDN's price correlate with its fundamentals
Growth
What is Eledon Pharmaceuticals's growth rate over time
Valuation
What is Eledon Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Eledon Pharmaceuticals's EPS has surged by 80% YoY but it has decreased by 29% QoQ
The stock's price to book (P/B) is 58% more than its 5-year quarterly average of 1.0
The company's equity fell by 3% QoQ
Efficiency
How efficient is Eledon Pharmaceuticals business performance
Eledon Pharmaceuticals's return on equity has surged by 82% YoY and by 39% QoQ
ELDN's return on assets has surged by 81% year-on-year and by 8% since the previous quarter
The return on invested capital has surged by 81% year-on-year and by 9% since the previous quarter
Dividends
What is ELDN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELDN.
Financial health
How did Eledon Pharmaceuticals financials performed over time
The total assets has soared by 100% YoY but it has contracted by 9% from the previous quarter
Eledon Pharmaceuticals's total liabilities has plunged by 51% YoY and by 21% from the previous quarter
The debt is 99% smaller than the equity
The company's debt to equity has surged by 150% YoY
The debt has declined by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.